Human herpesvirus 6 and cytomegalovirus in ileocolonic mucosa in inflammatory bowel disease

Scandinavian Journal of Gastroenterology

Volumn 46, Issue 11, 2011, Pages 1324-1333

  Sipponen, Taina ^a   Turunen, Ulla ^a   Lautenschlager, Irmeli ^a   Nieminen, Urpo ^a   Arola, Johanna ^a   Halme, Leena ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

CMV; Crohn's disease; HHV 6; IBD; ulcerative colitis

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; VIRUS ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; COLON MUCOSA; COLONOSCOPY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; CYTOMEGALOVIRUS; DISEASE ACTIVITY; DISEASE SEVERITY; ENTERITIS; HISTOPATHOLOGY; HUMAN; HUMAN HERPESVIRUS 6; ILEOCOLONIC MUCOSA; ILEUM; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; RECTUM; RECTUM BIOPSY; ULCERATIVE COLITIS;

ADULT; AGED; ANTIGENS, VIRAL; COLITIS, ULCERATIVE; COLON; CROHN DISEASE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 6, HUMAN; HUMANS; ILEUM; IMMUNOCOMPROMISED HOST; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 80054070379     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2011.605466     Document Type: Article

References (41)

1. Papadakis KA, Tung JK, Binder SW, Kam LY, Abreu MT, Targan SR, et al. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol 2001;96:2137-42.
2. Kandiel A, Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol 2006;101: 2857-65.
3. Rahier JF, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D'Haens G, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn's and Colitis 2009;2:47-91.
4. Flamand L, Komaroff AL, Arbuckle JH, Medveczky PG, Ablashi DV. Review, Part 1: Human herpesvirus-6 - Basic biology, diagnostic testing, and antiviral efficacy. J Med Virol 2010;82:1560-8.
5. Yamanishi K, Okuno T, Shiraki K, Takahashi M, Kondo T, Asano Y, et al. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet 1988;1:1065-7.
6. Lautenschlager I, Linnavuori K, Höckerstedt K. Human herpesvirus-6 antigenemia after liver transplantation. Transplantation 2000;69:2561-6.
7. Ljungman P, Singh N. Human herpesvirus-6 infection in solid organ and stem cell transplant recipients. J Clin Virol 2006;37:S87-91.
8. Razonable RR, Zerr DM. HHV-6, HHV-7 and HHV-8 in solid organ transplant recipients. Am J Transplant 2009;9: S97-103.
9. Vinnard C, Barton T, Jerud E, Blumberg E. A report of human herpesvirus 6-associated encephalitis in a solid organ transplant recipient and a review of previously published cases. Liver Transpl 2009;15:1242-6.
10. Amo K, Tanaka-Taya K, Inagi R, Miyagawa H, Miyoshi H, Okusu I, et al. Human herpesvirus 6B infection of the large intestine of patients with diarrhea. Clin Infect Dis 2003;36: 120-3.
11. Hentrich M, Oruzio D, Jager G, Schlemmer M, Schleuning M, Schiel X, et al. Impact of human herpesvirus-6 after haematopoietic stem cell transplantation. Br J Haematol 2005;128:66-72.
12. Halme L, Arola J, Hockerstedt K, Lautenschlager I. Human herpesvirus 6 infection of the gastroduodenal mucosa. Clin Infect Dis 2008;46:434-9.
13. Wakefield AJ, Fox JD, Sawyerr AM, Taylor JE, Sweenie CH, Smith M, et al. Detection of herpesvirus DNA in the large intestine of patients with ulcerative colitis and Crohn's disease using the nested polymerase chain reaction. J Med Virol 1992;38:183-90.
14. Lavagna A, Bergallo M, Daperno M, Sostegni R, Costa C, Leto R, et al. Infliximab and the risk of latent viruses reactivation in active Crohn's disease. Inflamm Bowel Dis 2007;13:896-902.
15. D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, et al. A review of activity indices and efficacyendpoints for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763-86.
16. Daperno M, D'Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: The SES-CD. Gastrointest Endosc 2004;60:505-12.
17. Moskovitz DN, Daperno M, Van Assche G. Defining and validating cut-offs for the Simple Endocopic Score for Crohn's Disease. Gastroenterology 2007;132:S1097.
18. Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME. Microscopic activity in ulcerative colitis: What does it mean? Gut 1991;32:174-8.
19. Halme L, Höckerstedt K, Lautenschlager I. Cytomegalovirus infection and development of biliary complications after liver transplantation. Transplantation 2003;75:1853-8.
20. Lautenschlager I, Hockerstedt K, Linnavuori K, Taskinen E. Human herpesvirus-6 infection after liver transplantation. Clin Infect Dis 1998;26:702-7.
21. The TH, van den Berg AP, Harmsen MC, van der Bij W, van Son WJ. The cytomegalovirus antigenemia assay: A plea for standardization. Scand J Infect Dis 1995;99:25-9.
22. Nakase H, Matsumura K, Yoshino T, Chiba T. Systematic review: Cytomegalovirus infection in inflammatory bowel disease. J Gastroenterol 2008;43:735-40.
23. Lawlor G, Moss AC. Cytomegalovirus in inflammatory bowel disease: Pathogen or innocent bystander. Inflamm Bowel Dis. 2010;16:1620-7.
24. Maher MM, Nassar MI. Acute cytomegalovirus infection is a risk factor in refractory and complicated inflammatory bowel disease. Dig Dis Sci 2009;54:2456-62.
25. Yoshino T, Nakase H, Ueno S, Uza N, Inoue S, Mikami S, et al. Usefulness of quantitative real-time PCR assay for early detection of cytomegalovirus infection in patients with ulcerative colitis refractory to immunosuppressive therapies. Inflamm Bowel Dis 2007;13:1516-21.
26. Kim JJ, Simpson N, Klipfel N. Cytomegalovirus infection in patients with active inflammatory bowel disease. Dig Dis Sci 2010;55:1059-65.
27. Nakase H, Yoshino T, Honzawa Y, Chiba T. Low prevalence of CMV infection in patients with Crohn's disease in comparison with ulcerative colitis: Effect of different immune response on prevalence of CMV infection. Dig Dis Sci 2010;55:1498-9.
28. Lempinen M, Halme L, Sarkio S, Arola J, Honkanen E, Turunen U, et al. CMV findings in the gastrointestinal tract in kidney transplantation patients, patients with end-stage kidney disease and immunocompetent patients. Nephrol Dial Transplant 2009;24:3533-9.
29. Shale MJ. The implications of anti-tumour necrosis factor therapy for viral infection in patients with inflammatory bowel disease. Br Med Bull 2009;92:61-77.
30. Criscuoli V, Mocciaro F, Orlando A, Rizzuto MR, Renda MC, Cottone M. Cytomegalovirus disappearance after treatment for refractory ulcerative colitis in 2 patients treated with infliximab and 1 patient with leukapheresis. Inflamm Bowel Dis 2009;15:810-11.
31. Torre-Cisneros J. Del Castillo M. Castón JJ. Castro MC. Pérez V. Collantes E. Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis. Rheumatology 2005;44:1132-5.
32. Helbling D, Breitbach TH, Krause M. Disseminated cytomegalovirus infection in Crohn's disease following antitumour necrosis factor therapy. Eur J Gastroenterol Hepatol 2002;14:1393-5.
33. D'Ovidio V, Vernia P, Gentile G, Capobianchi A, Marcheggiano A, Viscido A, et al. Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti- TNFalpha therapy. J Clin Virol 2008;43:180-3.
34. Knosel T, Schewe C, Petersen N, Dietel M, Petersen I. Prevalence of infectious pathogens in Crohn's disease. Pathol Res Pract 2009;205:223-30.
35. Sura R, Gavrilov B, Flamand L, Ablashi D, Cartun R, Colombel JF, et al. Human herpesvirus-6 in patients with Crohn's disease. APMIS 2010;118:394-400.
36. Halme L, Lempinen M, Arola J, Sarkio S, Höckerstedt K, Lautenschlager I. High frequency of gastroduodenal cytomegalovirus infection in liver transplant patients. APMIS 2008;116:99-106.
37. Mendez JC, Dockrell DH, Espy MJ, Smith TF, Wilson JA, Harmsen WS, et al. Human beta-herpesvirus interactions in solid organ transplant recipients. J Infect Dis 2001;183: 179-84.
38. DesJardin JA, Gibbons L, Cho E, Supran SE, Falagas ME, Werner BG, et al. Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection. J Infect Dis 1998;178:1783-6.
39. Petrisli E, Chiereghin A, Gabrielli L, Zanfi C, Lauro A, Piccirilli G, et al. Early and late virological monitoring of cytomegalovirus, Epstein-Barr virus, and human herpes virus 6 infections in small bowel/multivisceral transplant recipients. Transplant Proc 2010;42:74-8.
40. Streetz KL. Buhr T. Wedemeyer H. Bleck J. Schedel I. Manns MP.GökeMN.AcuteCMV-colitisin a patient witha history of ulcerative colitis. Scand J Gastroenterol 2003;38:119-22.
41. Hommes DW, Sterringa G, Van Deventer SJ, Tytgat GN, Weel J. The pathogenicity of cytomegalovirus in inflammatory bowel disease: A systematic review and evidence-based recommendations for future research. Inflamm Bowel Dis 2004;10:245-50.